Evolus (EOLS) Other Non-Current Assets (2017 - 2026)
Evolus' (EOLS) quarterly Other Non-Current Assets came in at $1.6 million in Q1 2026, up 83.11% YoY from $900000.0 in Q1 2025, and up 37.45% on a QoQ basis from $1.2 million in Q4 2025.
Evolus (EOLS) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Evolus (EOLS) has 10 years of Other Non-Current Assets data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 83.11% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 83.11% YoY) and the FY2025 annual result came in at $1.2 million, up 39.74% from the prior year.
- Other Non-Current Assets improved to $1.6 million in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $2.8 million in Q4 2022 to a low of $222000.0 in Q3 2023.
- A 5-year average of $1.4 million and a median of $1.2 million in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 1005.83% — and 2023, when it plunged 91.25%.
- Tracing EOLS's Other Non-Current Assets over 5 years: stood at $2.8 million in 2022, then plunged by 85.46% to $409000.0 in 2023, then surged by 109.78% to $858000.0 in 2024, then soared by 39.74% to $1.2 million in 2025, then soared by 37.45% to $1.6 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.6 million (Q1 2026), $1.2 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 13.00 Mn |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | 2.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.10 Mn |
| Mar 31, 2026 | 1.65 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.58 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Mar 31, 2025 | 900,000.00 |
| Dec 31, 2024 | 858,000.00 |
| Sep 30, 2024 | 858,000.00 |
| Jun 30, 2024 | 409,000.00 |
| Mar 31, 2024 | 409,000.00 |
| Dec 31, 2023 | 409,000.00 |
| Sep 30, 2023 | 222,000.00 |
| Jun 30, 2023 | 223,000.00 |
| Mar 31, 2023 | 2.68 Mn |
| Dec 31, 2022 | 2.81 Mn |
| Sep 30, 2022 | 2.43 Mn |
| Jun 30, 2022 | 2.55 Mn |
| Mar 31, 2022 | 2.65 Mn |
| Dec 31, 2021 | 2.76 Mn |
| Sep 30, 2021 | 240,000.00 |